Sugi Predict

Sugi Predict / Compounds / SCHEMBL667245

SCHEMBL667245

SCHEMBL667245

COC(=O)Cn1ccc(=O)[nH]c1=O

nearest known ligand 0.59

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 2/20 0.59
▸ LMNA P02545 1/20 0.59
▸ L3MBTL1 Q9Y468 1/20 0.54
▸ CA1 P00915 5/20 0.50
▸ CA2 P00918 5/20 0.50
▸ CA4 P22748 5/20 0.50
▸ CA9 Q16790 5/20 0.50
▸ DUT P33316 4/20 0.50
▸ KDM4E B2RXH2 2/20 0.48
▸ MEN1 O00255 1/20 0.48
▸ KMT2A Q03164 1/20 0.48
▸ ATM Q13315 1/20 0.48
▸ PKM P14618 1/20 0.47
▸ CRBN Q96SW2 2/20 0.46
▸ SMN1; SMN2 Q16637 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20529215 0.85 ALDH1A1 (0.44) ALDH1A1LMNAL3MBTL1CA1CA2
SCHEMBL6937491 0.83 L3MBTL1 (0.55) ALDH1A1LMNAL3MBTL1CA1CA2
SCHEMBL27703786 0.83 ALDH1A1 (0.55) ALDH1A1LMNAL3MBTL1CA1CA2
SCHEMBL11983580 0.82 ALDH1A1 (0.58) ALDH1A1LMNAL3MBTL1CA1CA2
SCHEMBL17254147 0.81 ALDH1A1 (0.66) ALDH1A1LMNAL3MBTL1CA1CA2
SCHEMBL2899640 0.80 ALDH1A1 (0.59) ALDH1A1LMNAL3MBTL1CA1CA2
SCHEMBL19370633 0.80 DUT (0.61) DUTCRBN
SCHEMBL11710750 0.79 ALDH1A1 (0.58) ALDH1A1LMNAL3MBTL1CA1CA2
SCHEMBL11710759 0.79 ALDH1A1 (0.58) ALDH1A1LMNAL3MBTL1CA1CA2
SCHEMBL5017554 0.77 DUT (0.49) ALDH1A1LMNAL3MBTL1DUTPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 892 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2014152909-A1 ALTERATION OF GENE EXPRESSION BY SYNTHETIC piRNAs AND BY ALTERATION OF piRNA FUNCTION IBIS BIOSCIENCES, INC. (US) 2014-09-25 — — WO claimed
US-20260138999-A1 REAGENTS AND THEIR USE FOR MODULAR ENANTIODIVERGENT SYNTHESIS OF C-P BONDS BRISTOL MYERS SQUIBB CO (US) 2026-05-21 — — US disclosed
US-12629412-B2 Betacoronavirus mRNA vaccines MODERNATX, INC. (US) 2026-05-19 — — US disclosed
CN-122038302-A Modified T cells and methods of making and using the same 哈佛学院校长同事会 2026-05-15 — — CN disclosed
US-20260130985-A1 NUCLEIC ACID-BASED UNIVERSAL VACCINE AND METHODS OF USE THEREOF ADVANCED RNA VACCINE ARV TECH INC (US) 2026-05-14 — — US disclosed
US-20260132404-A1 MODIFIED OLIGONUCLEOTIDES AND DOUBLE-STRANDED RNAS ALNYLAM PHARMACEUTICALS, INC. (US) 2026-05-14 — — US disclosed
US-12622960-B2 Varicella zoster virus (VZV) vaccine MODERNATX, INC. (US) 2026-05-12 — — US disclosed
US-20260108595-A1 BETACORONAVIRUS mRNA VACCINES MODERNATX, INC. (US) 2026-04-23 — — US disclosed
EP-4727955-A1 CYSTEINE-SUBSTITUTED RSV-F PROTEINS GlaxoSmithKline Biologicals S.A. (BE) 2026-04-22 — — EP disclosed
US-20260097110-A1 BETACORONAVIRUS mRNA VACCINES MODERNATX, INC. (US) 2026-04-09 — — US disclosed
EP-0683668-A4 COMPOSITIONS AND METHODS FOR TRANSDERMAL DRUG DELIVERY. AFFYMAX TECH NV (AN) 1997-12-29 — — EP disclosed
EP-0647133-A4 COMPOSITIONS AND METHODS FOR ENHANCED DRUG DELIVERY. AFFYMAX TECH NV (AN) 1997-10-29 — — EP disclosed
EP-0683668-A1 COMPOSITIONS AND METHODS FOR TRANSDERMAL DRUG DELIVERY AFFYMAX TECHNOLOGIES N.V. (AN) 1995-11-29 — — EP disclosed
EP-0647133-A1 COMPOSITIONS AND METHODS FOR ENHANCED DRUG DELIVERY AFFYMAX TECHNOLOGIES N.V. (AN) 1995-04-12 — — EP disclosed
WO-1994017792-A2 COMPOSITIONS AND METHODS FOR TRANSDERMAL DRUG DELIVERY AFFYMAX TECHNOLOGIES N.V. (AN) 1994-08-18 — — WO disclosed
EP-0586474-A1 PEPTIDE NUCLEIC ACIDS BUCHARDT, Ole (DK) 1994-03-16 — — EP disclosed
WO-1993025197-A1 COMPOSITIONS AND METHODS FOR ENHANCED DRUG DELIVERY AFFYMAX TECHNOLOGIES N.V. (AN) 1993-12-23 — — WO disclosed
WO-1992020702-A1 PEPTIDE NUCLEIC ACIDS BUCHARDT OLE (DK) 1992-11-26 — — WO disclosed
WO-1992019637-A1 OLIGONUCLEOTIDE ANALOGS CONTAINING THIOFORMACETAL LINKAGES GILEAD SCIENCES, INC. (US) 1992-11-12 — — WO disclosed
WO-1991006629-A1 OLIGONUCLEOTIDE ANALOGS WITH NOVEL LINKAGES GILEAD SCIENCES, INC. (US) 1991-05-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260097110-A1 BETACORONAVIRUS mRNA VACCINES RNMT, RNGTT, METTL16 ALDH1A1 4724/4885LMNA 555/4885L3MBTL1 331/4885
US-20260138999-A1 REAGENTS AND THEIR USE FOR MODULAR ENANTIODIVERGENT SYNTHESIS OF C-P BONDS RNGTT, CDA, DCTD ALDH1A1 2053/4885LMNA 1287/4885L3MBTL1 235/4885
US-12629412-B2 Betacoronavirus mRNA vaccines RNMT, RNGTT, METTL16 ALDH1A1 4705/4885LMNA 616/4885L3MBTL1 423/4885
US-20260132404-A1 MODIFIED OLIGONUCLEOTIDES AND DOUBLE-STRANDED RNAS RNASEL, NSUN2, ADAR ALDH1A1 4415/4885LMNA 241/4885L3MBTL1 38/4885
US-20260108595-A1 BETACORONAVIRUS mRNA VACCINES RNMT, METTL16, NSUN2 ALDH1A1 4565/4885LMNA 1182/4885L3MBTL1 254/4885
US-12622960-B2 Varicella zoster virus (VZV) vaccine NSUN2, RNMT, RNGTT ALDH1A1 4802/4885LMNA 1904/4885L3MBTL1 61/4885
US-20260130985-A1 NUCLEIC ACID-BASED UNIVERSAL VACCINE AND METHODS OF USE THEREOF UPF1, NSUN2, CD4 ALDH1A1 4843/4885LMNA 3144/4885L3MBTL1 158/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.